# Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease

> **NCT00004408** · PHASE3 · COMPLETED · sponsor: **Mast Therapeutics, Inc.** · enrollment: 300 (—)

## Conditions studied

- Sickle Cell Anemia

## Interventions

- **DRUG:** poloxamer 188

## Key facts

- **NCT ID:** NCT00004408
- **Lead sponsor:** Mast Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-11
- **Primary completion:** —
- **Final completion:** 1999-11
- **Target enrollment:** 300 (—)
- **Last updated:** 2012-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004408, "Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00004408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*